Friday, May 20, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Study shows Omicron less severe than Delta among COVID-19 hospitalized patients

by Medical Finance
in Coronavirus
Study: Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. Image Credit: anushkaniroshan/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

New research posted to the medRxiv* preprint server suggests the Omicron variant produces less severe COVID-19 symptoms than earlier severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants.

There was a 74% reduced risk of ICU admission, a 91% reduced risk of death, and no patients with Omicron infections needed mechanical ventilation. In addition, patients infected with Omicron recovered faster and were discharged sooner than patients with Delta infections.

While Omicron may be less severe than other variants, the surge in COVID-19 cases is devastating hospitals and causing severe burnout in frontline workers. An overload of COVID-19 hospitalization may lead to delays in medical care and potentially preventable deaths. The research team advises practicing multiple COVID strategies — wearing masks, isolating when infected, and getting vaccinated — to limit community transmission of Omicron and relieve an overwhelmed healthcare system.

Study: Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. Image Credit: anushkaniroshan/Shutterstock

Study: Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. Image Credit: anushkaniroshan/Shutterstock

Increasing rate of Omicron infections in late 2021

The researchers collected and analyzed data on positive COVID-19 cases in the Kaiser Permanente Southern California Healthcare system from November 30, 2021, to January 1, 2022.

A total of 88,576 positive COVID-19 cases were reported in outpatients from November 30, 2021, to January 1, 2022. In hospitalized patients, about 26.6% tested positive.

People with Omicron cases were more likely to be in their 20’s or 30’s than Delta cases. Additionally, Delta infections mostly came from lower-income neighborhoods, people who identify as white, and a high risk of comorbidities.

Omicron cases made up 75.5% of COVID-19 cases, including another 51.4% that tested in inpatients settings.

Trend-wise, the number of COVID-19 cases related to Omicron increased weekly. The only exception was the week of Christmas, in which the holiday break lagged the processing of tests.

Analyses showed that repeated infections were more likely with Omicron than Delta. People who had a COVID-19 infection 90 or more days since their current infection were 4.45-fold higher among Omicron cases than Delta cases. Moreover, vaccinated people were more likely to get infected with Omicron than with Delta.

When the researchers collected samples from 1,477 infected patients for sequencing, 100% of SARS-CoV-2 isolates detected through S gene target failure belonged to Omicron.

Of the 288,534 people who were outpatients and followed up and later tested positive, 88 were infected with Omicron and required hospitalization. There were 189 hospitalizations for Delta-related infections.

Attributes of cases with SGTF and non-SGTF samples detected. Panels include (A) test dates for all cases analyzed (truncated at 29 December 2022 to accommodate ±1 day jittering); (B) age distribution of all cases analyzed; (C) exposure history (prior documented infection and vaccination) among all cases analyzed; (D) dates of symptomatic hospital admission (truncated at 29 December 2022 to accommodate ±1 day jittering); (E) age distribution of cases with symptomatic hospitalizations; and (F) exposure history (prior documented infection and vaccination) among cases with symptomatic hospitalizations. Pink and grey bars correspond to detections with and without SGTF (interpreted as a proxy for SARS-CoV-2 Omicron variant infection; Table S1), respectively. Totals correspond to samples processed on RT-PCR TaqPath COVID-19 High-Throughput Combo Kit and do not reflect all cases at KPSC.

Attributes of cases with SGTF and non-SGTF samples detected. Panels include (A) test dates for all cases analyzed (truncated at 29 December 2022 to accommodate ±1 day jittering); (B) age distribution of all cases analyzed; (C) exposure history (prior documented infection and vaccination) among all cases analyzed; (D) dates of symptomatic hospital admission (truncated at 29 December 2022 to accommodate ±1 day jittering); (E) age distribution of cases with symptomatic hospitalizations; and (F) exposure history (prior documented infection and vaccination) among cases with symptomatic hospitalizations. Pink and grey bars correspond to detections with and without SGTF (interpreted as a proxy for SARS-CoV-2 Omicron variant infection; Table S1), respectively. Totals correspond to samples processed on RT-PCR TaqPath COVID-19 High-Throughput Combo Kit and do not reflect all cases at KPSC.

Severity of disease in hospitalized patients infected with Omicron versus Delta

Out of the 88 admitted Omicron-infected patients, 95.5% presented with symptoms. Similarly, 98.9% of Delta-infected patients were admitted with symptomatic infection.

About 7 patients infected with the Omicron variant required intensive care, including five who were first identified in outpatient settings. One person died. None received mechanical ventilation.

Compared to people admitted with infections from the Delta variant, 23 were admitted to the ICU, 14 patients died, and 11 patients required ventilation.

The daily risk of needing mechanical ventilation was significantly higher among patients with Delta infections than patients with Omicron infections.

About 79.7% of Omicron infections reported acute respiratory symptoms before hospitalization compared to the 80% reported with Delta infections. Once hospitalized, approximately 9.4% of Omicron cases developed respiratory problems. Almost 16% of Delta infections developed respiratory symptoms upon hospitalization.

Times to severe outcomes among cases with SGTF and non-SGTF infections first detected in outpatient settings. Panels include (A) symptomatic hospital admissions; (B) ICU admissions; (C) initiations of mechanical ventilation; and (D) mortality. Inset plots within each panel illustrate cumulative probabilities on the same y-axis scale as panel A. Shaded regions denote 95% confidence intervals. Green and violet correspond to detections with and without SGTF (interpreted as a proxy for SARS-CoV-2 Omicron variant infection), respectively.

Times to severe outcomes among cases with SGTF and non-SGTF infections first detected in outpatient settings. Panels include (A) symptomatic hospital admissions; (B) ICU admissions; (C) initiations of mechanical ventilation; and (D) mortality. Inset plots within each panel illustrate cumulative probabilities on the same y-axis scale as panel A. Shaded regions denote 95% confidence intervals. Green and violet correspond to detections with and without SGTF (interpreted as a proxy for SARS-CoV-2 Omicron variant infection), respectively.

Omicron cases showed greater rates of recovery after hospitalization than Delta

Approximately 83.5% of hospitalizations for Omicron cases were complete by January 1, 2022, compared to 77.8% of hospitalizations for Delta.

All patients hospitalized for an Omicron infection were discharged to home or home-based care. Only 92.9% of Delta cases were discharged from the hospital.

People with Omicron infections had nearly 70% shorter hospital stays than Delta infections. The average hospital stay for symptomatic Omicron infections was 1.5 days and 90% of patients were expected to recover within 3 days.

The average hospital stay for Delta infections was almost 5 days.

Study limitations

There was limited time for researchers to follow up on all COVID-19 cases and their rate of hospital discharge. Data on discharge was available for 84% of Omicron cases and for 78% of Delta cases. Additionally, follow-up data for Omicron infections were shorter since they occurred towards the end of the study period.

Because there is a possibility that COVID-19 testing among the Kaiser Permanente Southern California healthcare system is different than testing in the general population, the rate of Omicron versus non-Omicron infections and hospitalizations may differ at a population level.

*Important Notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Surveying communities may be a useful tool for predicting COVID-19 case trajectories

Researchers identify specific factors that influence attitudes about vaccines

by Medical Finance
May 20, 2022
0

Worldwide, vaccine hesitancy is proving to be a stumbling block to securing much needed protection against the spread of coronavirus...

Study: VarLOCK - sequencing independent, rapid detection of SARS-CoV-2 variants of concern for point-of-care testing, qPCR pipelines and national wastewater surveillance. Image Credit: Kateryna Kon/Shutterstock

VarLOCK approach for rapid detection of SARS-CoV-2 variants of concern and wastewater monitoring

by Medical Finance
May 20, 2022
0

A recent preprint study posted to the medRxiv* server discussed the expansion of the severe acute respiratory syndrome coronavirus...

Study: Comparison of Moderna Versus Pfizer-Biontech COVID-19 Vaccine Outcomes: A Target Trial Emulation Study In the U.S. Veterans Affairs Healthcare System. Image Credit: BaLL LunLa/Shutterstock

Comparing the Moderna and Pfizer-Biontech vaccines against SARS-CoV-2 infection

by Medical Finance
May 20, 2022
0

Several vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed to combat the ongoing coronavirus disease 2019...

Study: Mild SARS-CoV-2 infection in rhesus macaques is associated with viral control prior to antigen-specific T cell responses in tissues. Image Credit: CROCOTHERY/Shutterstock

Unraveling the early host-immune response to SARS-CoV-2 in mild COVID-19 infections

by Medical Finance
May 20, 2022
0

In a study posted recently to the bioRxiv* preprint server, researchers determined the early immune response to severe acute respiratory...

Study: A method for variant agnostic detection of SARS-CoV-2, rapid monitoring of circulating variants, detection of mutations of biological significance, and early detection of emergent variants such as Omicron. Image Credit: Lightspring/Shutterstock

New method for monitoring circulating SARS-CoV-2 variants and detecting new ones

by Medical Finance
May 20, 2022
0

After more than two years of the coronavirus disease (COVID-19) pandemic, there is still a constant threat of evolving strains...

Study: Temporary hold of mycophenolate boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients. Image Credit: PhotobyTawat/Shutterstock

Withdrawing steroid treatment found to boost SARS-CoV-2 vaccine-induced immunity in kidney transplant recipients

by Medical Finance
May 20, 2022
0

In a recent study posted to the medRxiv* pre-print server, a team of researchers investigated the impact of the fourth...

Next Post
Mutations in SARS-CoV-2 Omicron variant promote cell binding

Mutations in SARS-CoV-2 Omicron variant promote cell binding

Surveying communities may be a useful tool for predicting COVID-19 case trajectories

Study analyzes the impact of global trust in government due to the COVID-19 pandemic

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Long-term cardiovascular outcomes of COVID-19. Image Credit: Kateryna Kon/Shutterstock
    Study suggests people with COVID-19 exhibit increased risks and 12-month burdens of incident cardiovascular diseases
  • Study: Omicron BA.1 and BA.2 immune response in naïve and prior infected persons. Image Credit: Ninc Vienna / Shutterstock
    Antibody response following Omicron BA.2 infection is lower than BA.1
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply